Literature DB >> 8648902

Regulation of renin release is impaired after nitric oxide inhibition.

C Chatziantoniou1, M D Pauti, F Pinet, D Promeneur, J C Dussaule, R Ardaillou.   

Abstract

The aim of the present study was dual: first to establish that a preparation of afferent arterioles freshly isolated from the rat kidney is a suitable model to study renin release and synthesis, and second to investigate the effect(s) of nitric oxide (NO) inhibition on renin release in this model. Purification of renal microvessels was based on iron oxide infusion into the kidneys and separation of the afferent arterioles from glomeruli and connective tissue with a magnet. These microvessels express preprorenin mRNA, contain renin granules and release renin as evidenced by RT-PCR, immunocytochemistry and measurement of renin activity, respectively. Renin secretion was increased in isolated afferent arterioles after in vivo treatment with the diuretic furosemide (+300%) or in vitro treatment with the adenylyl cyclase activator forskolin (+50%), indicating that this vascular preparation responds appropriately to regulators of the renin-angiotensin system. Furthermore, in afferent arterioles isolated from control rats, renin release was positively correlated with total renin content (r = 0.85). In afferent arterioles isolated from rats chronically treated with the NO-synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME), forskolin was ineffective in modifying renin release despite stimulation of cAMP levels. In addition, the correlation between renin release and tissue renin content was disrupted. Similar results were obtained when cortical slices were used instead of afferent arterioles, suggesting that this defect in the regulation of renin release is independent of the presence of macula densa cells. To verify that the lack of regulation of renin release after L-NAME treatment was due to NO inhibition, the NO donor 3-morpholino-syndonimin-hydrochloride (SIN-1) was administered in afferent arterioles or cortical slices from kidneys of L-NAME-treated rats. In both preparations, SIN-1 reversed the L-NAME effect and re-established the responsiveness of renin release to forskolin and the relationship between renin release and renin content. These data indicate that the adenylyl cyclase-mediated mechanism regulating renin release is impaired when NO synthesis is inhibited.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648902     DOI: 10.1038/ki.1996.90

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

Review 1.  Tubular control of renin synthesis and secretion.

Authors:  Jurgen Schnermann; Josephine P Briggs
Journal:  Pflugers Arch       Date:  2012-06-05       Impact factor: 3.657

Review 2.  Convergence of major physiological stimuli for renin release on the Gs-alpha/cyclic adenosine monophosphate signaling pathway.

Authors:  Soo Mi Kim; Josephine P Briggs; Jurgen Schnermann
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

3.  Interest and limits of in vitro studies in renal vascular endocrinology.

Authors:  M Essig; S Ledoux; P L Tharaux; C Chatziantoniou; J C Dussaule
Journal:  Cell Biol Toxicol       Date:  1996-12       Impact factor: 6.691

4.  Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin.

Authors:  C Chatziantoniou; J J Boffa; R Ardaillou; J C Dussaule
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

5.  Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats.

Authors:  Bingong Li; Zeqi Zheng; Yunfeng Wei; Menghong Wang; Jingtian Peng; Ting Kang; Xin Huang; Jian Xiao; Yong Li; Zhe Li
Journal:  Cardiovasc Diabetol       Date:  2011-07-29       Impact factor: 9.951

6.  Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats.

Authors:  Bingong Li; Jian Xiao; Yong Li; Jian Zhang; Minghui Zeng
Journal:  Exp Ther Med       Date:  2013-08-27       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.